Emily K. Bergsland
Expertise in
15
conditions

Dr. Emily K. Bergsland

Oncology
1825 Fourth St., 
San Francisco, CA 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
1825 Fourth St., 
San Francisco, CA 

Overview

Dr. Emily Bergsland is a gastrointestinal oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center and the director of the UCSF Center for Neuroendocrine Tumors. She specializes in the multidisciplinary care of patients with neuroendocrine cancers. Bergsland's research is focused on better understanding why neuroendocrine tumors develop, identifying and testing new therapies, and improving outcomes in affected patients. Bergsland earned her medical degree at the University of Minnesota, then completed a residency in internal medicine and fellowship in medical oncology at UCSF.

Dr. Bergsland is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Carcinoid Syndrome, Pancreatic Islet Cell Tumor, Hepatectomy, and Liver Embolization.

Dr. Bergsland is board certified in American Board Of Internal Medicine, Medical Oncology. She is actively involved in clinical research, co-authoring 130 peer reviewed articles and participating in 4 clinical trials. Dr. Bergsland is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine, Medical Oncology

Fellowships

UCSF Medical Center House Staff, Oncology

Hospital Affiliations

Ucsf Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Center for Neuroendocrine Tumors
1825 Fourth St., San Francisco, CA 94158

Additional Areas of Focus

Dr. Bergsland has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Esophageal Cancer
Lynch Syndrome
Liver Cancer
Stomach Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Prospective Randomized Phase II Trial of Pazopanib (NSC #737754) Versus Placebo in Patients With Progressive Carcinoid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 2
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Enrollment Status: Completed
Publish Date: December 27, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Irinotecan, Paclitaxel
Study Phase: Phase 2
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.
Enrollment Status: Completed
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

130 Total Publications

ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.
ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.
Journal: Journal of the American College of Radiology : JACR
Published: February 04, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3372
Languages Spoken:
English
See accepted insurances

Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (25.7 miles away)
650-498-6000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.

Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3374
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Ashutosh Lal is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Lal is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Thalassemia, Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Frequently Asked Questions about Dr. Emily K. Bergsland

How do I make an appointment with Dr. Emily K. Bergsland?

You can book an appointment with Dr. Emily K. Bergsland by calling their office at 415-476-2212. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emily K. Bergsland a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emily K. Bergsland is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emily K. Bergsland specialize in?

While Dr. Emily K. Bergsland is a Oncology, they have specific expertise in Neuroendocrine Tumor, Carcinoid Syndrome, and Pancreatic Islet Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Emily K. Bergsland participate in research or clinical trials?

Yes. Dr. Emily K. Bergsland has published 130 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Emily K. Bergsland's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emily K. Bergsland accept my insurance?

Dr. Emily K. Bergsland accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 415-476-2212 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bergsland's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile